Cellular Immunotherapy for Septic Shock (CISS2)

Cellular Immunotherapy for Septic Shock (CISS2) A Phase II Randomized Controlled Trial

Septic shock is associated with substantial burden in terms of both mortality and morbidity for survivors of this illness. Pre-clinical sepsis studies suggest that mesenchymal stem (stromal) cells may modulate inflammation, enhance pathogen clearance and tissue repair and reduce death. Our team has completed a Phase I dose escalation and safety clinical trial that evaluated mesenchymal stem cells (MSCs) in patients with septic shock. The Cellular Immunotherapy for Septic Shock (CISS) trial established that MSCs appear safe and that a randomized controlled trial (RCT) is feasible. Based on these data, the investigators have planned a phase II RCT (CISS2) at several Canadian academic centres which will evaluate safety, signals for clinical efficacy, and continue to examine potential mechanisms of action and biological effects of MSCs in septic shock.

Study Overview

• Status: Unknown
• Conditions: Pathologic Processes; Sepsis; Systemic Inflammatory Response Syndrome; Inflammation; Shock; Septic Shock; Infection
• Intervention / Treatment: Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells; Other: Placebo

Detailed Description

Septic shock is a devastating illness and the most severe form of infection seen in the intensive care unit (ICU). It is characterized by cardiovascular collapse, failure of organs and is common with severe repercussions including a mortality of 20-40%. Survivors suffer long-term impairment in function and reduced quality of life (QOL). Despite decades of research examining different immune therapies, none has proven successful and supportive care remains the mainstay of therapy, at a cost of approximately 4-billion dollars in Canada annually. MSCs represent a potentially novel treatment for sepsis because in animal models, MSCs have been shown to modulate the immune system, increase pathogen clearance, restore organ function, and reduce death.

The Phase II multi-centre Cellular Immunotherapy for Septic Shock RCT (CISS2) will continue to evaluate safety, assess if there are signals for clinical efficacy and determine mechanisms of action and biological effects of MSCs in septic shock. To answer these aims, CISS2 will randomize 114 patients who are admitted to the ICU with septic shock to 300 million cryopreserved, allogeneic, bone marrow derived MSCs or placebo across 10 Canadian centres over approximately 2 years.

• Study Type: Interventional
• Enrollment (Anticipated): 114
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Josee Champagne; Phone Number: 73836 613-737-8899; Email: jochampagne@ohri.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

A participant must meet all three inclusion criteria to be eligible:

1. Admission to an Intensive Care Unit AND
2. Cardiovascular failure that is present within the first 24 hours of admission to the ICU and is defined by the requirement for at least 15 mcg/min of norepinephrine or at least 200 mcg/min of phenylephrine or at least 0.03 U/min of vasopressin, or a combination of norepinephrine and phenylephrine that is equivalent to the total required doses (e.g. norepinephrine 8 meq/min and phenylephrine 100 mcg/min) for at least 4 consecutive hours. Participants must still require vasopressor(s) at the time of MSC infusion to be eligible. AND

3. At least 1 additional organ failure, or organ hypoperfusion, as defined by the modified Multiple Organ Dysfunction Score (MODS). Criteria for organ dysfunction or organ hypoperfusion must be met within the first 24 hours of ICU admission. These include:

   1. Respiratory failure: mechanically ventilated with a positive end expiratory pressure (PEEP) of at least 5 cm H20, and a partial pressure of oxygen/fractional inspired oxygen concentration (P/F ratio) less than or equal to 200 on 2 separate occasions.
   2. Hematological failure: platelet count of less than or equal to 100 X 109 /L that has decreased by at least 50 x 109/L.
   3. Acute renal failure: acute renal insufficiency with a creatinine of greater than 200 umol/L that has increased by at least 50 umol/L, or the requirement for continuous renal replacement therapy, or for participants with known chronic renal failure but not on dialysis, a 50% increase in their baseline creatinine concentration.
   4. Organ hypoperfusion: a lactate of at least 4 mmol/L

Acute organ failures that meet eligibility criteria cannot have been present for more than 48 hours prior to admission to the ICU.

Exclusion Criteria:

1. Another form of shock (cardiogenic, hypovolemic, obstructive) that is considered by the treating critical care staff physician as the dominant cause of shock.
2. History of known chronic pulmonary hypertension with a WHO functional class of III or IV
3. History of severe chronic pulmonary disease requiring home oxygen
4. History of chronic severe cardiac disease including congestive heart failure or valvular dysfunction with a New York Heart Association Functional Class of III or IV, or severe ischemic heart disease with a Canadian Cardiovascular Society angina class score of III or IV.
5. History of severe chronic liver disease (Child class C)
6. Malignancy in the previous year (excluding resolved non-melanoma skin cancer). Participants will be excluded from the CISS2 trial if they have received any surgery, chemotherapy, or radiation for a malignancy in the previous 12 months.
7. Chronic immune suppression (chronic steroid use or chemotherapy)
8. Pregnant or lactating
9. Enrolment in another interventional study
10. Treating physicians' impression is that the participant is moribund and that death is imminent within the subsequent 12 hours of meeting eligibility criteria
11. Family, participant, or physician not committed to aggressive care. Any limitation of care will exclude the patient from enrolment in the CISS2 trial (ex: no intubation, no use of vasopressor agent(s), no renal support therapy).
12. Less than 18 years of age

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Mesenchymal Stromal Cells (MSCs); Intravenous infusion of 300 million Allogeneic, Bone Marrow-Derived Human Mesenchymal Stromal Cells	Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells; Cryopreserved Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
PLACEBO_COMPARATOR: Placebo; Intravenous infusion of Placebo, with excipients	Other: Placebo; Placebo, with excipients, will be administered intravenously.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The reduction in days on mechanical ventilation, or renal replacement therapy, or vasopressors.	The number of days free from each of these support measures.	Through to 28 days post-randomization
Incidence of treatment-emergent adverse events (Safety and tolerability)		Through to 28 days post-randomization

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Biological endpoints as markers of vascular permeability	Marker of vascular permeability (ex: Ang1 and 2), acute renal injury (ex: Urine TIMP2-IGFBP7, IL-18), muscle weakness (ex: micro RNA (miRNA) growth Differentiation Factor-15 and miR-181a)), mechanisms related to pathogen clearance (ex: cathelicidin, LL-37), and pro and anti-inflammatory cytokines (ex: IL-6, IL-8, IL-10, IL-1B and IL1-RA) related to potential MSC biological effects	At baseline, 1, 2, 3 and 7 days post-randomization
Mortality	All-cause mortality	Through to 12 months post-randomization
Organ Failure Scores	Sequential Organ Failure Assessment (SOFA) Score	Through to 90 days post-randomization
Organ Support Measures	Duration of mechanical ventilation and/or vasopressor agents and/or dialysis/renal replacement therapy	Through to 90 days post-randomization
Length of ICU Stay (in days)	Time in ICU	Number of elapsed days from admission until ICU discharge, up to one year
Length of Hospital Stay (in days)	Time in Hospital	Number of elapsed days from admission until hospital discharge, up to one year
Hospital Re-Admissions		At 28 days, 3 and 12 months post-randomization
Patient Reported Outcomes-FIM	Functional Independence Measure (FIM)	7 days and 6 months post-ICU discharge
Patient Reported Outcomes-SF 36	SF-36 Score	7 days and 6 months post-ICU discharge

Collaborators and Investigators

• Sponsor: Ottawa Hospital Research Institute
• Collaborators: Canadian Institutes of Health Research (CIHR); Stem Cell Network; Ontario Institute for Regenerative Medicine (OIRM)
• Investigators: Principal Investigator: Lauralyn McIntyre, MD, The Ottawa Hospital Research Institute

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): March 1, 2018
• Primary Completion (ANTICIPATED): February 1, 2020
• Study Completion (ANTICIPATED): October 1, 2020

Study Registration Dates

• First Submitted: August 28, 2017
• First Submitted That Met QC Criteria: December 5, 2017
• First Posted (ACTUAL): December 11, 2017

Study Record Updates

• Last Update Posted (ACTUAL): December 11, 2017
• Last Update Submitted That Met QC Criteria: December 5, 2017
• Last Verified: December 1, 2017

More Information

Terms related to this study

• Keywords: Randomized Controlled Trial; Mesenchymal Stem Cells; Allogeneic; Phase II; Mesenchymal Stromal Cells; Cryopreserved
• Additional Relevant MeSH Terms: Infections; Sepsis; Inflammation; Shock, Septic; Shock; Systemic Inflammatory Response Syndrome; Pathologic Processes
• Other Study ID Numbers: 201706

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No